Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Ascending Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Subjects With HER-2/NEU or HER-1/EGFR-Positive Tumors

NCT00146172 is registered in ClinicalTrials.gov with Puma Biotechnology, Inc. as lead sponsor.

NCT NCT00146172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00146172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Ascending Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Subjects With HER-2/NEU or HER-1/EGFR-Positive Tumors
Lead sponsor
Puma Biotechnology, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2003
Completion date
January 31, 2007
Enrollment
73 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms